Diversity in Clinical Trial Participants: Canada Holds Promise
Participant diversity in clinical trials can be quite challenging to achieve. With COVID the concern about appropriate demographic representation is…
The Canadian Landscape for Childhood Cancer Research
Pediatric Hematology Oncology is a relatively recent area of study. Only in the past 50 years have substantial advances taken…
2020 a Year Like No Other: What it Takes to Keep Ahead of Rapid Change
This time last year none of us imagined we were about to go through a year like no other, and…
Scimega, Canada’s Premier CRO, Introduces Julie Martin, CEO
Julie Martin, MSc, MBA, Lean certified, CEO and Co-owner has been part of the team at Scimega, since 2013. Her…
Overcome Oncology Clinical Trial Obstacles – 2020 Real World Evidence for 2021 and Beyond
Study start-up is one the most time-intensive areas within clinical drug development, accounting for two thirds or more of total…
Continued Importance of CRAs Supporting Role for Patient Centric Trials
The COVID-19 world-wide pandemic has forced the clinical trial industry to make rapid changes in order to continue protecting participant…
Smaller CROs May Do It Better, Quicker – Especially in Times of Crisis
Pursuit of a path from discovery to drug approval as quickly as possible is a clear objective for most biotech…
Looking for Key Clinical Trial Vendor Management Strategies?
Clinical trials, and in particular oncology studies, can be very complex and often involve multiple parties: Sponsor, CRO (sometimes several…
Consider This Region for Your Phase 3 Global Trial
As of May 2020 ClinicalTrials.gov lists 16,150 oncology trials registered as Recruiting, Not yet Recruiting Studies, and the chart below…
Recommendations for Quicker CTA Negotiation
Whether in Canada or any other country it is no secret that executing Clinical Trial Agreements (CTAs) is often the…